SCHEMBL5379844

SCHEMBL5379844

Cc1cnc(S(=O)(=O)c2ncc(C)c(-c3c(-c4ccc(C(F)(F)F)cc4)nn4cc(C(F)(F)F)ccc34)n2)nc1-c1c(-c2ccc(C(F)(F)F)cc2)nn2cc(C(F)(F)F)ccc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 4/20 0.50
CSNK1A1 P48729 1/20 0.37
CSNK1D P48730 1/20 0.37
CSNK1E P49674 1/20 0.37
PTGS2 P35354 3/20 0.34
LCK P06239 1/20 0.33
KIT P10721 1/20 0.33
SRC P12931 1/20 0.33
KDR P35968 1/20 0.33
KIF11 P52732 2/20 0.33
SCN9A Q15858 1/20 0.32
PTGER1 P34995 1/20 0.32
TYK2 P29597 2/20 0.32
NPC1 O15118 1/20 0.32
MAPT P10636 1/20 0.32
RAB9A P51151 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
TDP2 O95551 1/20 0.32
JAK2 O60674 1/20 0.32
JAK1 P23458 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5379839 0.88 MAPK14 (0.50) MAPK14CSNK1A1CSNK1DCSNK1EPTGS2
SCHEMBL7197244 0.84 MAPK14 (0.53) MAPK14CSNK1A1CSNK1DCSNK1ELCK
SCHEMBL7197240 0.83 MAPK14 (0.55) MAPK14CSNK1A1CSNK1DCSNK1ELCK
SCHEMBL6984106 0.76 MAPK14 (0.54) MAPK14CSNK1A1CSNK1DCSNK1ELCK
SCHEMBL5381902 0.75 MAPK14 (0.53) MAPK14CSNK1A1CSNK1DCSNK1EPTGS2
SCHEMBL5365336 0.71 MAPK14 (0.56) MAPK14CSNK1A1CSNK1DCSNK1EPTGS2
SCHEMBL5382328 0.71 MAPK14 (0.58) MAPK14CSNK1A1CSNK1DCSNK1EPTGS2
SCHEMBL5365522 0.70 MAPK14 (0.57) MAPK14PTGS2
SCHEMBL5377681 0.70 MAPK14 (0.69) MAPK14CSNK1A1CSNK1DCSNK1EPTGS2
SCHEMBL5379861 0.68 MAPK14 (0.55) MAPK14CSNK1A1CSNK1DCSNK1ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7166597-B2 Fused pyrazole derivatives being protein kinase inhibitors GLAXO GROUP LIMITED (GB) 2007-01-23 US disclosed
US-20040053942-A1 Fused pyrazole derivatives bieng protein kinase inhibitors SMITHKLINE BEECHAM CORPORATION 2004-03-18 US disclosed
EP-1311507-A1 FUSED PYRAZOLE DERIVATIVES BEING PROTEIN KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2003-05-21 EP disclosed
WO-2002016359-A1 FUSED PYRAZOLE DERIVATIVES BEING PROTEIN KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2002-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053942-A1 Fused pyrazole derivatives bieng protein kinase inhibitors RAF1, SBK3, MAP3K3 MAPK14 77/4885CSNK1A1 198/4885CSNK1D 291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.